Anthony Insogna is a leading pharmaceutical and biotechnology patent lawyer as recognized by clients, Chambers, and his peers. He has more than 28 years of experience enforcing and defending patents around the globe, driving patent portfolio strategy for drug candidates and FDA approved products, and conducting due diligence for life sciences companies, investment banks, and venture capital firms.
Anthony and his teams have achieved numerous victories in patent litigation, including the record-breaking $2.54B patent infringement verdict for Idenix (Merck & Co.) in December 2016. He and his teams successfully defended patents involving Humira® eight times (involving IPRs brought by Amgen, Coherus, and Sandoz); Revlimid®, one of the world's top-selling drugs; as well as Abraxane®. He has successfully enforced and defended patents for Kyowa Kirin's Potelligent® technology and defended Akebia Therapeutics against Fibrogen.
Anthony's patent strategies have protected several multimillion and multibillion dollar drugs including Revlimid®, Pomalyst®, Otezla®, Lunesta®, and Thalomid®. He has been counsel to Celgene since 1996. Furthermore, his IP strategies not only have been tested in litigation but also in M&A transactions, e.g., Dainippon Sumitomo Pharma's $2.6B acquisition of Sepracor (now Sunovion), Pfizer's $1.3B acquisition of Esperion, Amgen's $1.3B acquisition of Tularik, J&J's $970M acquisition of Cougar Biotechnology, MedImmune's $492M acquisition of U.S. Bioscience, and Merit Medical's $100M acquisition of BioSphere Medical.
Additional products for which Anthony has experience with litigation, prosecution, interferences, oppositions, invalidation actions, or transactions include: Allegra®, Brovana®, Clarinex®, Clofar®, Embospheres®, Ethyol®, Focalin®, Focalin XR®, HepaSpheres®, Ingrezza™, Istodax®, Kuvan®, Nesina®, Nithiodote®, Nuplazid®, Pristiq®, Relafen®, Rezield, Ritalin LA®, Synagis®, Tyzeka®, Vidaza®, Xyrem®, and Zytiga®.
Anthony founded the Firm's San Diego Office in 2004.
- September/October 2012
Obviousness-Type Double Patenting, Landslide, American Bar Association Vol. 5, No. 1
- March 26, 2009
Fresh start for biosimilars in 2009?, The Daily Transcript, San Diego's Business Daily
A Reinvestigation of the Reactions Occurring upon Photoexcitation of Cyclophexenome in the Presence of Triethylamine, The Journal of Organic Chemistry, Vol. 56, pages 1879-1882.
- February 3, 2017
Advanced IP Support of M&A Transactions in the Pharmaceutical Industry - Private Client CLE
- October 25, 2012
China Inbound Seminar: New Challenges and Opportunities for Foreign Investments in China
- October 24, 2012
Outbound Seminar "Managing Legal Risks in Global Expansion of Chinese Companies"
- August 9, 2012
Patent Issue Forum with David Kappos of the USPTO - Trade Secrets
- March 18, 2008
IP and the Life Sciences Industry, panel discussion moderator, USC Gould School of Law 2008 Intellectual Property Institute
- February 20, 2008
Issues and Challenges Facing Japanese University Biotech Ventures, The University of Tokyo and Mitsui Ventures
Issue and Challenge Facing Japanese University Biotech Venture
- April 26, 2006
Beijing International Pharmaceutical & Chemical - Intellectual Property Forum Introduction to U.S. Pharmaceutical Litigation and Global Impact
- September 28, 2005
Latest Thinking on Attacking/Defending Patent Rights in the U.S. Pharmaceutical and Biotechnology Markets, Henry Stewart Conference Studies
- March 22, 2005
2005 CALBIO Conference: The Face of Medicine in the Next Decade
- November, 2004
IP Biotechnology Patent Roundtable, The California Lawyer
- January 12, 2004
2004 JP Morgan Healthcare Conference, Panel Discussion Current Dynamics of Patent Law in the Pharmaceutical Industry
- June, 2002
Essential IP Due Diligence in Pharma/Biotech Alliance, American Conference Institute, Pharmaceutical/Biotech Collaborations and M&A
- May, 2002
Are Inventors Losing Their Rights As A Result Of Recent Federal Circuit Decisions, St. John's University School of Law, Intellectual Property Lecture
"Steeped in life sciences patents, he is skilled in handling enforcement, defense, deal due diligence and portfolio management alike."Chambers USA
- Fordham University (J.D. 1994); New York University (M.S. in Organic Chemistry 1990; B.S. in Organic Chemistry 1989)
- New York, District of Columbia, California, U.S. Supreme Court, U.S. Court of Appeals for the Federal Circuit, U.S. District Courts for the Southern District of California and Eastern and Southern Districts of New York, and registered to practice before the U.S. Patent and Trademark Office
Chambers: Band 1 (2015-2019)
Legal 500 US: elite leading lawyer (2017-2021)
IAM Patent 1000 (2014-2021)
Managing IP Star (2014-2021)
Acritas Star Lawyer (2020-2021)
WIPR Leaders (2016-2021)
Best Lawyers in America (2010-2022), including San Diego IP Litigation Lawyer of the Year (2021), Biotechnology Lawyer of the Year (2017), and Patent Lawyer of the Year (2015)
Daily Journal: Top IP Lawyers in California (2015-2021)
Daily Transcript: Top 100 Business Professionals (2016); Top Influentials (2017-2019)